John S. Kovach. M.D., CEO and Founder Dr. Kovach has directed leading National Cancer Institute–designated Comprehensive Cancer Centers at Mayo Clinic, Rochester, Minnesota and City of Hope National Medical Center, Los Angeles, California. He has extensive experience in medical oncology, anti-cancer drug pharmacology, and in applied medical research, particularly, the early evaluation of new anti-cancer drugs and the development and management of multi-disciplinary highly productive cancer research teams. Dr. Kovach, in consultation with LIXTE’s advisors and board, is responsible for the selection and prioritization of the scientific directions and goals of LIXTE.


James S. Miser, CMO Dr. Miser is a pediatric hematologist/oncologist, internationally recognized as an expert in the study and treatment of childhood cancers. His outstanding career includes leadership positions as Clinical Director, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children’s Hospital and Medical Center and Associate Member, Fred Hutchinson Cancer Research Center, Seattle, Washington; Chairman, Division of Pediatrics, Director, Department of Pediatric Hematology/Oncology, President and Chief Executive Officer, and Chief Medical Officer, all at City of Hope National Medical Center, Duarte, California. Since 2009, he has been a member of the Active Staff, Department of Pediatrics at City of Hope, most recently part-time, and Chair Professor, College of Medical Sciences and Technology, Taipei Medical University, Taipei, Taiwan.

Dr. Miser has extensive experience in the clinical development of new anti-cancer drugs for pediatric malignancies, leading many clinical trials at institutional and national cancer study groups. He is expert in the design and monitoring of clinical cancer trials and was a member of the Soft Tissue Sarcoma Strategy Group, and Member of the New Agents Executive and Steering Committee, Phase II Coordinator Children’s Cancer Group and Chairman, Data Monitoring Committee, National Wilms Tumor Society. He has authored more than a 100 peer reviewed articles dealing primarily with pediatric clinical cancer studies.


Robert N. Weingarten, CFO Mr. Weingarten is an experienced business consultant and advisor with a consulting practice focusing on accounting and SEC compliance issues. Since 1979, Mr. Weingarten has provided such financial consulting and advisory services, has acted as chief financial officer, and has served on the boards of directors of numerous public companies in various stages of development, operation or reorganization. Mr. Weingarten has experience in a variety of industries, including the pharmaceutical industry.

Mr. Weingarten has been a Director of Guardion Health Sciences, Inc. since June 2015 and Chairman of the board of directors since July 2020. Previously, Mr. Weingarten served as Lead Director on Guardion’s board of directors from January 2017 to March 2020. From July 2017 to June 2018, Mr. Weingarten was the Chief Financial Officer of Alltemp, Inc. From April 2013 to February 2017, Mr. Weingarten served on the board of directors of RespireRx Pharmaceuticals Inc. and also served as Vice President and Chief Financial Officer. Mr. Weingarten received a B.A. in Accounting from the University of Washington in 1974, a M.B.A. in Finance from the University of Southern California in 1975, and is a Certified Public Accountant (inactive) in the State of California.


Eric Forman, J.D., CAO Mr. Forman has led LIXTE’s business development as a consultant since 2013. Subsequently, Mr. Forman was appointed as the company’s Chief Administrative Officer. In his capacity as a consultant, and in his role as Chief Administrative Officer, his responsibilities include overseeing all internal operations, the development of science/business collaborations, and the management of our growing intellectual property portfolio. Prior to his involvement with our company, he served as Counsel and Senior Project Manager at Shore Group Associates managing in-house legal, tax, and regulatory affairs and supervising client relations for financial software and mobile application development teams.

As an attorney, Mr. Forman has represented and advised both technology and biotechnology companies, entrepreneurs, non- profits, and start-ups with a focus on intellectual property, licensing, corporate structure and transactions. Mr. Forman earned a B.A. degree Cum Laude from Loyola Marymount University and a J.D. from the Benjamin N. Cardozo School of Law. He has an active law license and is a member of the New York State Bar Association.



Gil N. Schwartzberg, JD, ScD (hon) has been a consultant to LIXTE since the company’s inception. Prior to which, he was the Chief Executive Officer and Chairman of the Board of Directors of the City of Hope National Medical center, an NCI designated Comprehensive Cancer Center. Mr. Schwartzberg was the only person in the City of Hope’s 100-year history to hold both CEO and Board Chair positions. He is currently Chairman Emeritus for life. His leadership and perceptive insights into the complexities of integrating basic science research with state-of-the-art compassionate patient care and the accreditation of the Graduate School of Biological Sciences at City of Hope during his tenure as president, were recognized by that institution in 2003 by awarding Mr. Schwartzberg a Doctor of Science degree, the first such degree awarded by the graduate school. During his extensive career he has held positions of major responsibility in: law, biomedicine, banking, apparel/shoe manufacturing and fast food retailing. He has overseen the process by which over a dozen companies have become publicly traded, on all of the United States securities exchanges.


Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare’s Clinical Research Institute. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. He is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEXTM Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.


Francis Johnson, Ph.D. is a chemical pharmacologist who consults for and collaborates with LIXTE in the systematic development of new anti-cancer substances based on a knowledge of defined biochemical abnormalities in specific types of human cancers. Dr. Johnson is a highly experienced synthetic organic chemist who has broad knowledge of pharmacology. He is the principal inventor on approximately 70 patents many of which deal with pharmacologic agents and his academic research, which includes theoretical studies on stereochemistry, synthetic work on many natural products and extensive work on DNA damage, has been reported in more than 170 peer-reviewed publications. Dr. Johnson is also the president of Chem-Master International Inc., a company founded in 1994, that specializes both in the custom synthesis of chemical intermediates and in the development of new drug substances. Dr. Johnson spent the early part of his career working in the Eastern Research Laboratory, a research institute near Boston, run by the Dow Chemical Co. Since 1974 he has occupied Professorships in both Chemistry and in Pharmacological Sciences at Stony Brook University.